Completed PHASE3 INTERVENTIONAL 3-arm NCT00168844

Tiotropium / Respimat One-Year Study

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Comparison of One-Year Treatment of Two Doses (5mg and 10mg) of Tiotropium Inhalation Solution Delivered by the Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: Boehringer Ingelheim

Conditions Pulmonary Disease, Chronic Obstructive

Interventions Placebo Tiotropium Inhalation Solution

Updated 6 times since 2017 Last updated: May 15, 2014 Started: Jan 31, 2003 Primary completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Pulmonary Disease, Chronic Obstructive, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Angers, France , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Athens, Greece , Berlin, Germany , Beuvry, France , Birmingham, United Kingdom , Breda, Netherlands , Bristol, United Kingdom and 62 more locations